

10/ 776,876

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:30:08 ON 22 APR 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:30:27 ON 22 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7  
DICTIONARY FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10776876.str



chain nodes :

7 8 9 10 14 15 18 19 20 21

10/ 776,876

ring nodes :

1 2 3 4 5 6

chain bonds :

1-18 2-8 4-7 5-14 8-9 9-10 14-15 18-19 19-20 19-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 1-18 2-3 2-8 3-4 4-5 4-7 5-6 8-9 9-10 14-15 19-20 19-21

exact bonds :

5-14 18-19

isolated ring systems :

containing 1 :

G1:O,S

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
14:CLASS 15:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 14:30:56 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 208 TO ITERATE

100.0% PROCESSED 208 ITERATIONS

5 ANSWERS

10/ 776,876

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3295 TO 5025  
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 14:31:04 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 4584 TO ITERATE

100.0% PROCESSED 4584 ITERATIONS 189 ANSWERS  
SEARCH TIME: 00.00.01

L3 189 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 14:31:10 ON 22 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Apr 2005 VOL 142 ISS 18  
FILE LAST UPDATED: 21 Apr 2005 (20050421/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 10 L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:215748 CAPLUS

DOCUMENT NUMBER: 139:78433

TITLE: The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2

AUTHOR(S): Blackie, Josie A.; Bloomer, Jackie C.; Brown, Murray J. B.; Cheng, Hung-Yuan; Hammond, Beverley; Hickey, Deirdre M. B.; Iffe, Robert J.; Leach, Colin A.; Lewis, V. Ann; Macphie, Colin H.; Milliner, Kevin J.; Moores, Kitty E.; Pinto, Ivan L.; Smith, Stephen A.; Stansfield, Ian G.; Stanway, Steven J.; Taylor, Maxine A.; Theobald, Colin J.

CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, SG1 2NY, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(6), 1067-1070

CODEN: BMCLEB; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:78433

AB Modification of the pyrimidone 5-substituent in clin. candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A2 with sub-nanomolar potency. Cyclopentyl fused derivative

21. SB-480848, showed an enhanced in vitro and in vivo profile vs. SB-435495 and has been selected for progression to man.

IT 552857-42-0P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(design and structure activity of lipoprotein-associated phospholipase A2 inhibitor SB-480848)


RN 552857-42-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-(2-aminoethyl)-2-[[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:154252 CAPLUS

DOCUMENT NUMBER: 138:205073

TITLE: Preparation of 2,5-substituted 1-(aminocarbonylalkyl)-pyrimidin-4-ones with Lp-PLA2 inhibitory activity for the treatment of atherosclerosis.

INVENTOR(S): Elliott, Richard Leonard; Leach, Colin Andrew; Smith, Stephen Allan

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015786	A1	20030227	WO 2002-EP9068	20020813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2001-19793 A 20010814

OTHER SOURCE(S): MARPAT 138:205073

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [1; R1, R2 = (un)substituted (hetero)aryl; R3 = Het(alkyl) (wherein Het = (un)substituted 5-7 membered heterocyclyl, bonded directly through a ring carbon atom, comprising N atom and optionally O or S); R4 = (un)substituted (hetero)aryl; R5 = (un)substituted aryl; n = 1-4; X = O, S; Z = CR13R14 (R13, R14 = H, alkyl, or R13 and R14 together with the intervening carbon atom form cycloalkyl)] which are inhibitors of lipoprotein-associated phospholipase A2 (Lp-PLA2)

and are of use in therapy, in particular for treating atherosclerosis, were prepared thus, amidation of N-[1-(2-methoxyethyl)piperidin-4-yl]-4-(4-trifluoromethylphenyl)benzylamine with 1-(carboxymethyl)-2-(2,3-difluorobenzylthio)-5-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-one (prepn. given) in the presence of HATU and (iso-Pr)2NH in DMF afforded II. The compds. I described in the examples were tested for Lp-PLA2 inhibition and demonstrated IC50 values in the range 1 to 0.01 nM.

IT 500132-05-0P 500132-06-0P 500132-08-1P

500132-09-2P 500132-13-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,5-substituted 1-(aminocarbonylalkyl)-pyrimidin-4-ones with


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

Lp-PLA2 inhibitory activity for the treatment of atherosclerosis)

RN 500132-05-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-5-[[[1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 500132-06-9 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-5-[[[1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 500132-05-8

CMF C40 H41 F5 N6 O3 S

10/ 776,876


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



RN 500132-08-1 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-(1-ethyl-4-piperidinyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 500132-09-2 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-(1-ethyl-4-piperidinyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 500132-08-1  
CMF C39 H39 F5 N6 O2 S


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 87-69-4  
CMF C4 H6 O6


Absolute stereochemistry.



RN 500132-13-8 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:641070 CAPLUS

DOCUMENT NUMBER: 138:280725

TITLE:

The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man

AUTHOR(S):

Blackie, Josie A.; Bloomer, Jackie C.; Brown, Murray J. B.; Cheng, Hung-Yuan; Elliott, Richard L.; Hammond, Beverley; Hickey, Deirdre M. B.; Ife, Robert J.; Leach, Colin A.; Lewis, V. Ann; Macphie, Colin H.; Milliner, Kevin J.; Moores, Kitty E.; Pinto, Ivan L.; Smith, Stephen A.; Stansfield, Ian G.; Stamway, Steven J.; Taylor, Maxine A.; Theobald, Colin J.; Whittaker, Caroline M.

CORPORATE SOURCE:

GlaxoSmithKline, Medicines Research Centre, Stevenage, SG1 2NY, UK

SOURCE:

Bioorganic &amp; Medicinal Chemistry Letters (2002), 12(18), 2603-2606

CODEN: BMCLES; ISSN: 0960-894X

PUBLISHER:

Elsevier Science Ltd.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB

The introduction of a functionalized amido substituent into a series of 1-(biphenylmethylacetamido)-pyrimidones has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A2 with sub-nanomolar potency and very encouraging developability properties. Diethylaminoethyl derivative, SB-435495, was selected for progression to man.

IT

304694-18-6P 304694-31-3P 304694-39-1P, SB

435495 304694-66-4P 304694-69-6P 304694-69-7P

503534-59-6P 503534-60-9P 503534-61-0P

503534-62-1P 503534-63-2P 503534-64-3P

503534-65-4P 503534-66-5P 503534-67-6P

503534-68-7P 503534-69-8P 503534-70-1P

503534-71-2P 503534-72-3P 503534-73-4P

503534-74-5P 503534-75-6P 503534-76-7P

503534-77-8P 503534-78-9P 503534-79-0P

503534-80-3P 503534-81-4P 503534-82-5P

503534-83-6P 503534-84-7P 503534-85-8P

503534-86-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrimidone SB-435495 as a lipoprotein-associated phospholipase A2 inhibitor)

RN 304694-18-6 CAPLUS


CN

1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A

RN 304694-31-3 CAPLUS


CN

1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A

RN 304694-39-1 CAPLUS


CN

1(4H)-Pyrimidineacetamide, N-2-[(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-A




PAGE 2-A

RN 304694-66-4 CAPLUS



CN

1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 304694-68-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 503534-60-9 CAPLUS  
CN Glycine, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[[2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 503534-61-0 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 2-A


RN 304694-69-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[[(4'-trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 503534-59-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-[[[(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 503534-62-1 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A






L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 2-A



RN 503534-63-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-ethyl-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

RN 503534-64-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A



PAGE 2-A

RN 503534-65-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-(2-methoxyethyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A



PAGE 2-A

RN 503534-66-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-(2-(dimethylamino)-2-oxoethyl)-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A




PAGE 2-A

RN 503534-67-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-(2-(ethylamino)ethyl)-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-68-7 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)]]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-69-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-[[bis(1-methylethyl)amino]ethyl]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)]]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-70-1 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-[(i-Pr)2N-CH2-CH2]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)]]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-71-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-[(1-piperidinyl)ethyl]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)]]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-72-3 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
 -[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[2-  
 (4-morpholinyl)ethyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-73-4 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-  
 -[ethyl(2-hydroxyethyl)amino]ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-  
 methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-74-5 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-[bis(2-hydroxyethyl)amino]ethyl]-N-[(4'-  
 chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-  
 methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-75-6 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-  
 -(dimethylamino)propyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-  
 pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-76-7 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-(diethylamino)propyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-77-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-78-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-79-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN	503534-80-3	CAPLUS
CN	1-(4H)-Pyrimidineacetamide, 2-[[{4-fluorophenyl)methyl}thio]-N-(2-hydroxyethyl)-5-[[1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)	

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-81-4 CAPLUS  
CN Glycine, N-[(2-{[4-(4-fluorophenyl)methyl]thio}-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidinyl)acetyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-82-5 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-(dimethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[[1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-83-6 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[4-fluorophenyl]methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[2-(4-morpholinyl)-2-oxoethyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-84-7 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(2-(ethylamino)ethyl)-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-85-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[2-(1-piperidinylethyl)ethyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 503534-86-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[3-(dimethylamino)propyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:900066 CAPLUS

DOCUMENT NUMBER: 136:256730

TITLE:

AUTHOR(S):

Potent, orally active inhibitors of  
lipoprotein-associated phospholipase A2:  
1-(biphenylmethylamidoalkyl)-pyrimidones  
Boyd, Helen F.; Fell, Stephen C. M.; Hickey, Deirdre  
M. B.; Ife, Robert J.; Leach, Colin A.; MacPhee, Colin  
H.; Milliner, Kevin J.; Pinto, Ivan L.; Rawlings, D.  
Anthony; Smith, Stephen A.; Stansfield, Ian G.;  
Stanway, Steven J.; Theobald, Colin J.; Whittaker,  
Caroline M.

CORPORATE SOURCE: GlaxoSmithKline, Medicines Research Centre, Stevenage,  
SG1 2NY, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001),  
Volume Date 2002, 12(1), 51-55

CODEN: BMCLES; ISSN: 0960-894X

Elsevier Science Ltd.

PUBLISHER:


DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GI

CASREACT 136:256730



AB A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A2 with high potency in whole human plasma. Two compds. (I, R=1-methylpyrazol-4-yl or 5-(2-methoxypyrimidin-5-yl)) demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects.

IT 304694-18-6P 304694-66-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(1-(biphenylmethylamidoalkyl)-pyrimidones as inhibitors of lipoprotein-associated phospholipase A2)

RN 304694-18-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



IT 304694-26-6P 304694-64-2P 405139-98-2P

405139-99-3P 405140-00-3P 405140-01-4P

405140-02-5P 405140-03-6P 405140-04-7P

405140-05-8P 405140-06-9P 405140-07-0P

405140-08-1P 405140-09-2P 405140-10-5P

405140-11-6P 405140-12-7P 405140-13-8P

405140-14-9P 405140-15-0P 405140-16-1P

405140-17-2P 405140-18-3P 405140-19-4P

405140-20-7P 405140-21-8P 405140-22-9P

405140-23-0P 405140-24-1P 405140-25-2P

405140-26-3P 405140-27-4P 405140-28-5P

405140-29-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(1-(biphenylmethylamidoalkyl)-pyrimidones as inhibitors of lipoprotein-associated phospholipase A2)


RN 304694-26-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(2-(4-morpholinyl)-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A


RN 304694-66-4 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-A




PAGE 2-A




RN 304694-64-2 CAPLUS


CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 405139-98-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[[1,1'-biphenyl]-4-ylmethyl]-2-[[4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 405139-99-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[[4-fluorophenyl]methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI)




RN 405140-02-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[4-(fluorophenyl)methyl]thio]-N-methyl-5-[[1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 405140-03-6 CAPLUS  
CN 1(4H)-Pyrimidinacetamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[[4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-  
yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-00-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-3-ylmethyl)-2-[[4-(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 405140-01-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-2-ylmethyl)-2-((4-fluorophenyl)methyl)thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX

PAGE 1-A



PAGE 2-A




RN 405140-04-7 CAPLUS  
CN 1(4H)-Pyrimidinacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-  
(9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-05-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-bromo[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-06-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-07-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(3'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-08-1 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(2'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-09-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-10-5 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 405140-11-6 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[[[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A


RN 405140-12-7 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[[[(4'-methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 405140-13-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-fluorophenyl)methyl]thio-5-[(2-methoxy-5-pyrimidinyl)methyl]thio-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-14-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]thio-5-[(4-fluorophenyl)methyl]thio-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-15-0 CAPLUS

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 405140-16-1 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, N-[(1,1'-biphenyl)-4-ylmethyl]thio-5-[(4-fluorophenyl)methyl]thio-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 405140-17-2 CAPLUS


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluorophenyl)methyl]thio-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A


RN 405140-18-3 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluorophenyl)methyl]thio-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-19-4 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[[4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-  
yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-20-7 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI)  
(CA INDEX NAME)




RN 405140-21-8 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo-  
9CI) (CA INDEX NAME)




RN 405140-22-9 CAPLUS  
CN 1(4B)-Pyridinebutanamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-  
methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 405140-23-0 CAPIUS  
CN 1(4H)-Pyrimidinebutanamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[4-fluoromethyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo-  
(9CI) (CA INDEX NAME)




RN 405140-24-1 CAPLUS  
CN 1-(4H)-Pyrimidinebutanamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
-[[4-(4-fluorophenyl)methyl]thio]-5-[[2-methoxy-5-pyrimidinyl)methyl]-N-  
methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-25-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-[[2-(1-piperazinyl)-5-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 405140-28-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-[[2-(trifluoromethyl)-5-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 2-A



RN 405140-26-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 405140-27-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 405140-29-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:518627 CAPLUS  
 DOCUMENT NUMBER: 135:326949  
 TITLE: 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A2  
 AUTHOR(S): Bloomer, J. C.; Boyd, H. F.; Hickey, D. M. B.; Ife, R. J.; Leach, C. A.; Macphie, C. H.; Milliner, K. J.; Pinto, I. L.; Rawlings, D. A.; Smith, S. A.; Stansfield, I. G.; Stanway, S. J.; Taylor, M. A.; Theobald, C. J.; Whittaker, C. M.  
 CORPORATE SOURCE: GlaxoSmithKline, Harlow, Essex, CM19 5AV, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(14), 1925-1929  
 CODEN: BMCLEB; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB The lipophilic 1-substituent in a series of 1-((amido-linked)-alkyl)-pyrimidones, inhibitors of recombinant lipoprotein-associated phospholipase A2, has been modified to give inhibitors of high potency in human plasma and enhanced physicochem. properties. Phenylpiperazineacetamide derivative (I) shows very promising oral activity.


IT 224774-14-5P 224775-00-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(arylpiperazinylamidoalkyl)-pyrimidones as orally active inhibitors of lipoprotein-associated phospholipase A2)


RN 224774-14-5 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(9Z)-octadecenyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224775-00-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2001:177448 CAPLUS  
 DOCUMENT NUMBER: 135:28649  
 TITLE: The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2  
 AUTHOR(S): Boyd, H. F.; Hammond, B.; Hickey, D. M. B.; Ife, R. J.; Leach, C. A.; Lewis, V. A.; Macphie, C. H.; Milliner, K. J.; Pinto, I. L.; Smith, S. A.; Stansfield, I. G.; Theobald, C. J.; Whittaker, C. M.  
 CORPORATE SOURCE: New Frontiers Science Park, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, CM19 5AV, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(5), 701-704  
 CODEN: BMCLEB; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Modification of the pyrimidine 5-substituent in a series of 1-((amidolinked)-alkyl)pyrimidones, lipophilic inhibitors of lipoprotein-associated phospholipase A2, has given inhibitors of nanomolar potency and improved physicochem. properties. One of the compds. was identified as a potent, highly water soluble, CNS penetrant inhibitor suitable for i.v. administration.

IT 224774-53-2 224774-54-3 224774-63-4  
 224775-00-2 224775-01-3 224775-02-4  
 224775-03-5 224775-04-6 259532-11-1  
 259532-12-2 259532-13-3 259532-14-4  
 259532-15-5 259532-16-6 259532-17-7  
 320785-90-8 343852-15-3 343852-16-4  
 343852-17-5 343852-18-6 343852-21-1  
 343852-23-3 343852-25-5 343852-26-6  
 343852-27-7 343852-28-8 343852-29-9  
 343852-30-2 343852-31-3


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (identification and structure-activity relationships of inhibitors of lipoprotein-associated phospholipase A2)

RN 224774-53-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-54-3 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 224774-63-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-[[5-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 224775-00-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[4-fluorophenyl)methyl]thio]-5-[[2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 224775-01-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[4-fluorophenyl)methyl]thio]-5-[[2-methoxy-5-pyrimidinyl)methyl]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 259532-12-2 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 5-[[[2-[[[4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-13-3 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 5-[[[2-[[[4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-14-4 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 5-[[[2-[[[4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


RN 224775-02-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[2-ethoxy-5-pyrimidinyl)methyl]thio]-2-[[[4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)



RN 224775-03-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo-5-[[2-(phenylmethoxy)-5-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 224775-04-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[2-dihydro-2-oxo-5-pyrimidinyl)methyl]thio]-N-dodecyl-2-[[[4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 259532-11-1 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 5-[[[2-[[[4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 259532-15-5 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 5-[[[2-[[[4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-16-6 CAPLUS  
CN 1(2H)-Pyrimidineacetamide, 5-[[[2-[[[4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl)methyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-17-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[2-dihydro-1-[2-(morpholinyl)-2-oxoethyl]-2-oxo-5-pyrimidinyl)methyl]thio]-N-dodecyl-2-[[[4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 320785-90-9 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 343852-15-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-1-methyl-2-oxo-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)




RN 343852-16-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1-ethyl-1,2-dihydro-2-oxo-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 343852-23-3 CAPLUS  
CN 1(2H)-Pyrimidineacetamide, 5-[[[2-[[[(4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl]methyl]-2-oxo-N-propyl- (9CI) (CA INDEX NAME)




RN 343852-25-5 CAPLUS  
CN 1(2H)-Pyrimidineacetamide, 5-[[[2-[[[(4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl]methyl]-2-oxo-N-propyl- (9CI) (CA INDEX NAME)




RN 343852-26-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 343852-17-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-1-methyl-2-oxo-5-pyrimidinyl]methyl]-N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 343852-18-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-1-(2-hydroxyethyl)-2-oxo-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)




RN 343852-21-1 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-1-(2-hydroxyethyl)-2-oxo-5-pyrimidinyl]methyl]-N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 343852-27-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-1-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-2-oxo-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)



RN 343852-28-8 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-2-oxo-1-[2-oxo-2-(3-oxo-1-piperazinyl)ethyl]-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)




RN 343852-29-9 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-2-oxo-1-[2-oxo-2-(3-oxo-1-piperazinyl)ethyl]-5-pyrimidinyl]methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)




RN 343852-30-2 CAPLUS



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1(2H)-Pyrimidineacetamide, 5-[[1-[2-(dodecylmethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-4-oxo-5-pyrimidinyl]methyl]-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 343952-31-3 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 5-[[1,2-dihydro-2-oxo-1-[2-oxo-2-(3-oxo-1-piperazinyl)ethyl]-5-pyrimidinyl]methyl]-N-dodecyl-2-[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:844936 CAPLUS  
 DOCUMENT NUMBER: 134:115922  
 TITLE: N-1-Substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2  
 AUTHOR(S): Hickey, Deirdre M. B.; Iffe, Robert J.; Leach, Colin A.; Macphie, Colin H.; Milliner, Kevin J.; Moores, Kitty E.; Pinto, Ivan L.; Porter, Rod A.; Rawlings, D. Anthony; Smith, Stephen A.; Stansfield, Ian G.; Tew, David G.; Theobald, Colin J.; Whittaker, Caroline M.  
 CORPORATE SOURCE: SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Essex, CH19 5AW, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(22), 2557-2561  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB From two related series of 2-(alkylthio)pyrimidones, a novel series of 1-[[amidolinked]-alkyl]pyrimidones was designed as nanomolar inhibitors of human lipoprotein-associated phospholipase A2. These compds. show greatly enhanced activity in isolated plasma. Selected derivs. are orally active with a good duration of action.

IT 224774-13-4P 224774-14-5P 224774-15-6P  
 224774-27-0P 224774-29-2P 224774-30-5P  
 224774-32-7P 224774-45-2P 224774-50-9P  
 224774-51-0P 224774-53-2P 224774-54-3P  
 224774-63-4P 320785-89-5P 320785-90-8P  
 320785-91-9P 320785-92-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (orally active inhibitor of lipoprotein-associated phospholipase A2)  
 RN 224774-13-4 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octadecyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 224774-14-5 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(92)-9-octadecyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 224774-15-6 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(9E)-9-octadecyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 224774-27-0 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, N-decyl-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-29-2 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-heptyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-30-5 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-hexyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-32-7 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-45-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[6-(4-fluorophenyl)hexyl]-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-50-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(9Z)-9-octadecenyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 224774-51-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(9E)-9-octadecenyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 320785-89-5 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-heptyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 320785-90-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 320785-91-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-heptyl-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 320785-92-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-butyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-53-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-54-3 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 224774-63-4 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:790485 CAPLUS  
 DOCUMENT NUMBER: 133:335244  
 TITLE: Preparation of 1-acetamido-2-(aryalkylthio)-4-pyrimidinones as lipoprotein associated phospholipase A2 inhibitors  
 INVENTOR(S): Fenwick, Ashley Edward; Hickey, Deirdre Mary; Bernadette; Ifo, Robert John; Leach, Colin Andrew; Pinto, Ivan Leo; Smith, Stephen Allan  
 PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK  
 SOURCE: PCT Int. Appl., 74 pp.  
 CODEN: P1XX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066567	A1	20001109	WO 2000-EP3727	20000425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371671	AA	20001109	CA 2000-2371671	20000425
EP 1175408	A1	20020130	EP 2000-920741	20000425
EP 1175408	B1	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103216	T2	20020422	TR 2001-200103216	20000425
BR 2000010220	A	20020514	BR 2000-10220	20000425
JP 2002543190	T2	20021217	JP 2000-615598	20000425
AU 765003	B2	20031009	AU 2000-41203	20000425
NZ 515137	A	20031031	NZ 2000-515137	20000425
EP 1479671	A1	20041124	EP 2004-77397	20000425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY				
AT 283845	E	20041215	AT 2000-920741	20000425
NO 2001005329	A	20011031	NO 2001-5329	20011031
ZA 2001008991	A	20021020	ZA 2001-8991	20011031
US 2004167142	A1	20040826	US 2004-776876	20040211
PRIORITY APPLN. INFO.:				
			GB 1999-10048	A 19990501
			GB 2000-2096	A 20000128
			EP 2000-920741	A3 20000425
			WO 2000-EP3727	W 20000425
			US 2002-30661	A3 20020422
OTHER SOURCE(S):		MARPAT 133:335244		
G1				

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB The title compds. (I) [wherein R1, R2, and R4 = independently (un)substituted (hetero)aryl; R3 = H or (un)substituted alkyl; R5 = (un)substituted aryl; n = 1-4, preferably 1 or 3; X = O or S; Z = CR13R14; R13 and R14 = independently H or alkyl; or CR13R14 = cycloalkyl] were prepared as inhibitors of the phospholipase A2 enzyme Lp-PLA2 for the treatment of atherosclerosis. For example, II was formed by amidation of 1-(carboxymethyl)-2-(4-fluorobenzylthio)-5-((1-methylpyrazol-4-yl)methyl)pyrimidin-4-one with N-methyl-4-(4-chlorophenyl)benzylamine (preparation for both starting materials given). I inhibited recombinant Lp-PLA2 enzyme activity with IC50 values in the range of 0.001 to 0.0005 µM.

IT 304694-35-7P 304694-39-1P 304694-48-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 1-acetamido-2-(aryalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(carboxymethyl)-2-(aryalkylthio)-4-pyrimidinones with (hetero)aryalkylamines for the treatment of atherosclerosis)  
 RN 304694-35-7 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-2-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-2-[(diethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)  
 CH 1  
 CRN 304694-31-3  
 CMF C37 H40 Cl F N6 O2 S

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

F

CH 2  
 CRN 110-16-7  
 CMF C4 H4 O4


Double bond geometry as shown.



RN 304694-39-1 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-2-[(diethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A


F

RN 304694-48-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-2-[(diethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 304694-18-6P 304694-20-0P 304694-24-4P  
304694-26-6P 304694-29-9P 304694-31-3P  
304694-32-4P 304694-33-5P 304694-36-8P  
304694-37-9P 304694-41-5P 304694-43-7P  
304694-43-9P 304694-52-8P 304694-53-2P  
304694-56-2P 304694-60-8P 304694-64-2P  
304694-68-6P 304694-69-7P 304694-71-1P  
304694-43-0P

RL: BAC (Biological activity or effecter, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

[preparation of 1-acetamido-2-(arylalkylthio)-4-pyrimidinone Lp-PIA2 inhibitors and hydrazide of 1-(carboxymethyl)-2-(arylalkylthio)-4-pyrimidinones with (hetero)arylalkylamines for the treatment of

PAGE 1-A




PAGE 2-A



RN 304694-24-4 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

RN 304694-18-6 CAPIUS  
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
 [(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-  
 yl)methyl]-4-oxo-9C1) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 304694-20-0 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[4-(4-fluorophenyl)methyl]thio]- $\alpha$ -methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)-1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


● HC1

RN 304694-26-6 CAPLUS  
CN 1-(4H)-Pyrimidinacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-  
[[4-(4-fluorophenyl)methyl]thio]-N-methyl-5-[[2-(4-morpholinyl)-5-  
pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 304694-29-9 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 304694-31-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 304694-32-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 304694-33-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 304694-31-3  
CMF C37 H40 Cl F N6 O2 S

PAGE 1-A




PAGE 2-A

|  
F

CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.




RN 304694-36-8 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-(2-(diethylamino)ethyl)-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monomethanesulfonate (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
trihydroxy-24-oxocholan-24-yl]amino]-, compd. with N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-(2-(diethylamino)ethyl)-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidineacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-31-3  
CMF C37 H40 Cl F N6 O2 S

PAGE 1-A



PAGE 2-A

|  
F

CM 2


CRN 81-24-3  
CMF C26 H45 N O7 S

Absolute stereochemistry.

CM 1

CRN 304694-31-3  
CMF C37 H40 Cl F N6 O2 S

PAGE 1-A



PAGE 2-A


|  
F

CM 2

CRN 75-75-2  
CMF C H4 O3 S


RN 304694-37-9 CAPLUS  
CN Ethanesulfonic acid, 2-[(3a,5b,7a,12a)-3,7,12-

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 304694-41-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A

F


● HCl

RN 304694-43-7 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-39-1  
 CMF C38 H40 F4 N6 O2 S

PAGE 1-A



PAGE 2-A

F


L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A

F


CM 2

CRN 77-92-9  
 CMF C6 H8 O7



RN 304694-52-8 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 87-69-4  
 CMF C4 H6 O6

Absolute stereochemistry.




RN 304694-45-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-39-1  
 CMF C38 H40 F4 N6 O2 S


PAGE 1-A



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A

F




● HCl


RN 304694-53-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl)methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-48-2  
 CMF C37 H39 F4 N7 O2 S

PAGE 1-A






CM 2

CRN 87-69-4  
CMF C4 H6 O6


Absolute stereochemistry.



RN 304694-56-2 CAPLUS

CN 1-(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[2-(1-piperidinylethyl)-N-[[6-[(trifluoromethyl)phenyl]-3-pyridinyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 304694-55-1  
CMF C38 H39 F4 N7 O2 S

CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



RN 304694-60-8 CAPLUS


CN 1-(4H)-Pyrimidineacetamide, N-(2-aminoethyl)-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 304694-64-2 CAPLUS

CN 1-(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 304694-68-6 CAPLUS

CN 1-(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-(2-(dimethylamino)ethyl)-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)






L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 2-A

I  
F

RN 304694-69-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[2-(dimethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

I  
F

RN 304694-71-1 CAPLUS  
CN Glycine, N-[[2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, sodium salt (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A



PAGE 2-A

I  
F

Na


RN 304695-43-0 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-39-1  
CMF C38 H40 F4 N6 O2 S

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

I  
F

CM 2

CRN 104-15-4  
CMF C7 H8 O3 S




IT 304694-59-5 304694-66-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 1-acetamido-2-(arylalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(carboxymethyl)-2-(arylalkylthio)-4-pyrimidinones with (hetero)arylalkylamines for the treatment of atherosclerosis)

RN 304694-59-5 CAPLUS  
CN Glycine, N-[[2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

I  
F

RN 304694-66-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[[4'-(chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[[2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (5CI) (CA INDEX NAME)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:144863 CAPLUS  
 DOCUMENT NUMBER: 132:180594  
 TITLE: Preparation of pyrimidinone derivatives for the treatment of atherosclerosis  
 INVENTOR(S): Leach, Colin Andrew; Smith, Stephen Allan  
 PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010980	A1	20000302	WO 1999-EP6093	19990818
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1105377	A1	20010613	EP 1999-942894	19990818
EP 1105377	B1	20031008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523402	T2	20020730	JP 2000-566254	19990818
AT 251613	E	20031015	AT 1999-942894	19990818
US 6559155	B1	20030506	US 2001-763492	20010221
PRIORITY APPL. INFO.:			GB 1998-18375	A 19980821
			GB 1999-2009	A 19990129
			WO 1999-EP6093	W 19990818

OTHER SOURCE(S): MARPAT 132:180594  
 GI




AB The title compds. (I; R1 = CO2H, salt thereof, CO2R10, etc.; R2 = mono- or

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

bicyclic arom. ring system, mono- or bicyclic heteroarom. ring system; R3 = alkyl, cycloalkyl, cycloalkylalkyl, etc.; W = SO2, a bond; X = O, S; Y = Al-A2-A3 (wherein A1 and A3 = a bond, alkylene; A2 = a bond, O, S, etc.; providing that when A2 = O, S, SO, SO2 or CONH, A3 contains at least two carbon atoms linking the A2 group and the CH2 group); R10 = alkyl, pharmaceutically acceptable in vivo hydrolysable ester] which are inhibitors of the enzyme LpPLA2, and are useful in treating inter alia atherosclerosis, were prepd. E.g., a 3-step synthesis of pyrimidinone II starting with 1-undecyl-5-(2-methoxypyrimidin-5-ylmethyl)-2-thiouracil, was given. Compds. I were tested for Lp-PLA2 inhibition and showed IC50 of 0.0004-3.2 µM.

IT 259532-13-39  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrimidinones as antiatherosclerotics)

RN 259532-13-3 CAPLUS  
 CN 1(ZH)-Pyrimidineacetic acid, 5-[[1-[2-(dodecylmethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-4-oxo-5-pyrimidinyl]methyl]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 259532-11-1P 259532-12-2P 259532-14-4P  
 259532-15-5P 259532-16-6P 259532-17-7P  
 259532-18-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidinones as antiatherosclerotics)

RN 259532-11-1 CAPLUS  
 CN 1(ZH)-Pyrimidineacetic acid, 5-[[2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-5-oxo-5-pyrimidinyl]methyl]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 259532-12-2 CAPLUS  
 CN 1(ZH)-Pyrimidineacetic acid, 5-[[2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-4-oxo-5-pyrimidinyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-14-4 CAPLUS  
 CN 1(ZH)-Pyrimidineacetic acid, 5-[[1-[2-(dodecylmethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-4-oxo-5-pyrimidinyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-15-5 CAPLUS  
 CN 1(ZH)-Pyrimidineacetamide, 5-[[2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-1-[2-(methyloctylamino)-2-oxoethyl]-5-oxo-5-pyrimidinyl]methyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 259532-16-6 CAPLUS  
CN 1(2H)-Pyrimidineacetamide, 5-[[1-[2-(dodecylmethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-5-oxo-5-pyrimidinyl]methyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 259532-17-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[1,2-dihydro-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-5-pyrimidinyl]methyl]-N-dodecyl-2-[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 259532-18-8 CAPLUS  
CN 1(2H)-Pyrimidineacetic acid, 5-[[1-[2-(dodecylmethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-1,4-dihydro-5-oxo-5-pyrimidinyl]methyl]-2-oxo-, sodium salt (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




● Na

IT 224775-00-2P 224775-01-3P 224775-05-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrimidinones as antiatherosclerotics)

RN 224775-00-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[4-(4-fluorophenyl)methyl]thio]-5-[[2-methoxy-5-pyrimidinyl]methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 224775-01-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[4-(4-fluorophenyl)methyl]thio]-5-[[2-methoxy-5-pyrimidinyl]methyl]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)





RN 224775-05-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[1,2-dihydro-2-oxo-5-pyrimidinyl]methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 1999:325924 CAPLUS  
DOCUMENT NUMBER: 130:352278  
TITLE: Preparation of pyrimidinone derivatives as Ip-PLA2 inhibitors  
INVENTOR(S): Hickey, Deirdre Mary Bernadette; Ife, Robert John; Leach, Colin Andrew; Pinto, Ivan Leo; Porter, Roderick Alan; Smith, Stephen Allan  
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK  
SOURCE: PCT Int. Appl., 210 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924420	A1	19990520	WO 1998-EP6988	19981023
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309177	AA	19990520	CA 1998-2309177	19981023
AU 9911575	A1	19990531	AU 1999-11575	19981023
EP 1028955	A1	20000823	EP 1998-954482	19981023
EP 1028955	B1	20030716		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SI				
JP 2001522044	T2	20011120	JP 2000-520434	19981023
ES 2203988	T3	20040416	ES 1998-954482	19981023
ZA 9810112	A	20000505	ZA 1998-10112	19981105
US 6417192	B1	20020709	US 2000-530713	20000628
US 2002120139	A1	20020829	US 2002-115452	20020402
PRIORITY APPLN. INFO.:				
			GB 1997-23352	A 19971106
			GB 1997-23358	A 19971106
			WO 1998-EP6988	W 19981023
			US 2000-530713	A3 20000628
OTHER SOURCE(S):		MARPAT 130:352278		
GI				


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The title compds. I [Z is a bond and R1 is halo, or Z is CR3R4 wherein R3 and R4 are each hydrogen, alkyl, or CR3R4 = cycloalkyl ring; R1 is aryl or heteroaryl group optionally substituted by 1 - 4 substituents; X = O, S; Y is ALA2A3 in which A1 and A3 each represent a bond or alkylene, and A2 represents a bond or O, S, etc.; a proviso is given; R2 is aryl or heteroaryl group optionally substituted by 1 - 4 substituents; W is a bond and R7 is hydrogen; or W is SO2 or a bond; R7 is R1 or hydrocarbyl group (further detail on said hydrocarbyl group is given)] are prepared. I are useful in the treatment of atherosclerosis (no data). For example, pyrimidinone derivative II was prepared. Compds. of this invention were found to have IC50 values in the range 0.0001 to 60 µM in the test for lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibition.

IT 224778-23-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and therapeutic effect of pyrimidinone derivs. as Lp-PLA2 inhibitors)


RN 224778-23-8 CAPLUS  
 CN 1(4H)-Pyrimidinehexanamide, N-butyl-2-[[[3,4-difluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



IT 224774-11-2P 224774-13-4P 224774-14-5P


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.




RN 224774-15-6 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-N-(9Z)-9-octadecenyl]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 224774-16-7 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, N-dodecyl-2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-17-8 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-N-nonyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

224774-15-6P 224774-16-7P 224774-17-8P  
 224774-19-0P 224774-20-3P 224774-21-4P  
 224774-22-5P 224774-23-6P 224774-24-7P  
 224774-25-8P 224774-26-9P 224774-27-0P  
 224774-28-1P 224774-29-2P 224774-30-5P  
 224774-31-6P 224774-32-7P 224774-33-8P  
 224774-34-9P 224774-35-0P 224774-36-1P  
 224774-37-2P 224774-38-3P 224774-39-4P  
 224774-40-7P 224774-43-0P 224774-44-1P  
 224774-45-2P 224774-47-4P 224774-48-5P  
 224774-49-6P 224774-50-9P 224774-51-0P  
 224774-52-1P 224774-53-2P 224774-54-3P  
 224774-56-5P 224774-57-6P 224774-59-8P  
 224774-60-1P 224774-61-2P 224774-62-3P  
 224774-63-4P 224774-65-6P 224774-73-6P  
 224774-77-0P 224774-81-6P 224774-82-7P  
 224774-83-8P 224774-85-0P 224774-86-1P  
 224774-87-2P 224774-90-7P 224774-92-9P  
 224774-93-0P 224774-94-1P 224774-96-3P  
 224774-97-4P 224774-98-5P 224774-99-6P  
 224775-00-2P 224775-01-3P 224775-02-4P  
 224775-03-5P 224775-04-6P 224775-05-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of pyrimidinone derivs. as Lp-PLA2 inhibitors)

RN 224774-11-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 5-[[[2-methoxy-4-pyridinyl)methyl]-4-oxo-2-[[[phenylmethyl]thio]- (9CI) (CA INDEX NAME)




RN 224774-13-4 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-N-octadecyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-14-5 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-N-(9Z)-9-octadecenyl]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 224774-19-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[[[6-(4-fluorophenyl)heptyl]thio]-2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 224774-20-3 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, N-[[[11-(dimethylamino)undecyl]thio]-2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-21-4 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, N-[[[3-ethoxypropyl]thio]-2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-22-5 CAPLUS  
CN L-lysine, N6-[4-[2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-1-oxobutyl]-N2-[(phenylmethoxy)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224774-23-6 CAPLUS  
CN Hexanoic acid, 6-[[4-[2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-1-oxobutyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 224774-24-7 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-N-hexyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


RN 224774-28-1 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, N-decyl-5-[(1,2-dihydro-1-methyl-2-oxo-4-pyridinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo- (9CI) (CA INDEX NAME)




RN 224774-29-2 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-heptyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-30-5 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-hexyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-31-6 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-nonyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)





RN 224774-25-8 CAPLUS  
CN Carbanic acid, [5-[[4-[2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-1-oxobutyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 224774-26-9 CAPLUS  
CN Carbanic acid, [6-[[4-[2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-1-oxobutyl]amino]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 224774-27-0 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, N-decyl-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-32-7 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 224774-33-8 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-N-pentyl-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-34-9 CAPLUS  
CN 1(4H)-Pyrimidinebutanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-N-hexyl-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-35-0 CAPLUS  
CN 1(4H)-Pyrimidinehexanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-N-(2-methoxyethyl)-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-36-1 CAPLUS  
CN 1(4H)-Pyrimidinehexanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-37-2 CAPLUS  
CN 1(4H)-Pyrimidinehexanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-N-methyl-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-38-3 CAPLUS  
CN 1(4H)-Pyrimidinehexanamide, N-butyl-2-[[[(3,4-difluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 224774-43-0 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-(3-butoxypropyl)-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-44-1 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(6-hydroxyhexyl)-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 224774-45-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[6-(4-fluorophenyl)hexyl]-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 224774-39-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[(1R)-2-(hexylamino)-1-methyl-2-oxoethyl]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224774-40-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[(1S)-2-(hexylamino)-1-methyl-2-oxoethyl]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 224774-47-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-N-tridecyl- (9CI) (CA INDEX NAME)



RN 224774-48-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-N-tetradecyl- (9CI) (CA INDEX NAME)




RN 224774-49-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octadecyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-50-9 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(9Z)-9-octadecenyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 224774-51-0 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(9E)-9-octadecenyl-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 224774-52-1 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-decyl-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-53-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)


RN 224774-59-8 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(2-methoxyethyl)-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-60-1 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-61-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-N-[2-(4-pentylphenyl)ethyl]-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-62-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[2-(hexylamino)-2-oxoethyl]-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)





RN 224774-54-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-octyl-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-56-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)]-N-undecyl- (9CI) (CA INDEX NAME)




RN 224774-57-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-63-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)



RN 224774-65-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-73-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-N-nonyl-4-oxo-5-(5-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 224774-77-0 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-[11-(dimethylamino)undecyl]-2-[[[(4-

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-81-6 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, N-[2-[[6-(4-fluorophenyl)hexyl]oxy]ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-82-7 CAPLUS  
 CN D-Lysine, N6-[[2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]acetyl]-N2-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-87-2 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-90-7 CAPLUS  
 CN 1(4H)-Pyrimidinebutanamide, 5-[[[(1,2-dihydro-1-methyl-2-oxo-4-pyridinyl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-hexyl-4-oxo- (9CI) (CA INDEX NAME)




RN 224774-92-9 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[2-(hexylmethylamino)-2-oxoethyl]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-83-8 CAPLUS  
 CN Hexanoic acid, 6-[[[2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 224774-85-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-nonyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-86-1 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N,N-dimethyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-93-0 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[2-(hexylamino)-2-oxoethyl]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)





RN 224774-94-1 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-N-[2-(hexylmethylamino)-2-oxoethyl]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-96-3 CAPLUS  
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-N-phenyl-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 224774-97-4 CAPLUS  
CN Benzoic acid, 4-[[[2-[[[4-(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 224774-98-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-4-oxo-N-(phenylmethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 224774-99-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N,N-dibutyl-2-[[[4-(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224775-00-2 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, N-dodecyl-2-[[[4-(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 224775-01-3 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 224775-02-4 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[(2-methoxy-5-pyrimidinyl)methyl]-2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo- (9CI) (CA INDEX NAME)



RN 224775-03-5 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-N-octyl-4-oxo-5-[[2-(phenylmethoxy)-5-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 224775-04-6 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-N-dodecyl-2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 224775-05-7 CAPLUS  
CN 1(4H)-Pyrimidineacetamide, 5-[[[1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT